Yes, a new
mAbs, a new failure!
Wilex AG (Xetra:WL6) fell EUR 2.40 (62%) to
EUR 1.50 on Tuesday after Rencarex girentuximab missed the primary endpoint of
improving median disease-free survival (DFS) vs. placebo in the Phase III
ARISER trial to treat clear cell renal cell carcinoma (RCC). ARISER was
evaluating once-weekly Rencarex for 24 weeks following complete or partial
surgical removal of the affected kidney in patients with no detectable
metastases. Rencarex is a chimeric mAb against carbonic anhydrase IX (CAIX).
Well, let’s
see who will fail next…
No comments:
Post a Comment